Meeting
2024 ASCO Annual Meeting
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Authors
Yasmin Karimi
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Yasmin Karimi , Pau Abrisqueta , Sven de Vos , Marcel Nijland , Fritz Offner , Kojo Osei-Bonsu , Ali Rana , Kimberly G. Archer , Yaou Song , Raul Cordoba , Lorenzo Falchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT04663347
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7032)
DOI
10.1200/JCO.2024.42.16_suppl.7032
Abstract #
7032
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
First Author: Pau Abrisqueta
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont
Poster
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
First Author: Tongyu Lin